Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4972021 | 0.92 | ALDH1A1 (0.47) | KMT2ALMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL2421336 | 0.91 | MAPK9 (0.55) | KMT2ALMNASMN1; SMN2ALDH1A1MAPK9 | |
| SCHEMBL7434456 | 0.90 | KMT2A (0.48) | KMT2ALMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL2422063 | 0.84 | MAPK9 (0.52) | KMT2ALMNASMN1; SMN2ALDH1A1MAPK9 | |
| SCHEMBL2423054 | 0.82 | MAPK9 (0.59) | KMT2ALMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL3480198 | 0.82 | MAPK9 (0.54) | KMT2AALDH1A1MAPK9MAPK10MEN1 | |
| SCHEMBL2423962 | 0.81 | MAPK9 (0.58) | KMT2ALMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL2422619 | 0.81 | MAPK9 (0.52) | KMT2ALMNASMN1; SMN2ALDH1A1MAPK9 | |
| SCHEMBL3480063 | 0.81 | MAPK9 (0.51) | KMT2ALMNASMN1; SMN2ALDH1A1MAPK9 | |
| SCHEMBL6431701 | 0.80 | MAPK9 (0.59) | KMT2ALMNAPOLBALDH1A1MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | claimed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | claimed |
| CN-1189467-C | Pharmaceutically active sulfonamide derivatives | APPLIED RES SYSTEM ARS HOLDING (AN) | 2005-02-16 | — | — | CN | claimed |
| CN-1377347-A | Pharmaceutically active sulfonamide derivatives | APPLIED RESEARCH SYSTEMS (NL) | 2002-10-30 | — | — | CN | claimed |
| EP-1088821-A1 | Pharmaceutically active sulfonamide derivatives | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-04 | — | — | EP | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | LABORATOIRES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005097116-A1 | COMPOSITION COMPRISING A JNK INHIBITOR AND CYCLOSPORIN | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-10-20 | — | — | WO | disclosed |
| CN-1189467-C | Pharmaceutically active sulfonamide derivatives | APPLIED RES SYSTEM ARS HOLDING (AN) | 2005-02-16 | — | — | CN | disclosed |
| CN-1377347-A | Pharmaceutically active sulfonamide derivatives | APPLIED RESEARCH SYSTEMS (NL) | 2002-10-30 | — | — | CN | disclosed |
| EP-1218374-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001023378-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-05 | — | — | WO | disclosed |
| EP-1088821-A1 | Pharmaceutically active sulfonamide derivatives | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | MAPKAPK2, JUN, MAP3K13 | KMT2A 2086/4885LMNA 3925/4885SMN1; SMN2 4502/4885 |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | KMT2A 2101/4885LMNA 4291/4885SMN1; SMN2 4273/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | KMT2A 847/4885LMNA 4626/4885SMN1; SMN2 4847/4885 |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | KMT2A 1484/4885LMNA 4163/4885SMN1; SMN2 4875/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | KMT2A 847/4885LMNA 4626/4885SMN1; SMN2 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.